IGC Pharma, Inc. (IGC)
| Market Cap | 28.03M-31.7% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 100.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 299,908 |
| Open | 0.29 |
| Previous Close | 0.28 |
| Day's Range | 0.28 - 0.29 |
| 52-Week Range | 0.23 - 0.45 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 3 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About IGC
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
$IGC stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IGC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IGC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IGC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IGC Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IGC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IGC from public contracts
Source: USAspending.gov
IGC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IGC’s recent data — informational, not investment advice